These platforms leverage distinct biological advantages over traditional CAR-T cells, including MHC-unrestricted recognition, natural tumor infiltration, cytokine-driven immunomodulation, and reduced risk of cytokine release syndrome. The gene discussed is HLA-C; the disease is neoplasm.